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Short Communication
T lymphocyte subsets in the peripheral blood of patients
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Breast cancer is the most common form of
malignancy in women and despite advances in
diagnosis and therapy of this condition, there has
been little change in the prognosis over the past 30
years (Osborne et al., 1980). The role of the
immune system in breast cancer has stimulated
considerable interest and research, in particular it
has been noted that breast cancer patients have
demonstrably impaired cell-mediated immune
responses compared to normal individuals
(Whittaker & Clarke 1971). Some workers have
provided evidence that the number of thymus-
dependent lymphocytes (T cells) in the peripheral
blood is reduced (Keller et al., 1976; Cervantes et
al., 1979) while Menconi et al. (1979) showed that
in advanced forms of the disease delayed
hypersensitivity responses to purified-protein
derivative were significantly reduced. Most
attention however has focussed on in vitro
functional tests of cell-mediated immunity such as
the transformation of T cells by
phytohaemaglutinin (PHA) which have been shown
to be impaired (Conesa, 1979; Jerrells, 1978).
Zembala et al. (1977) suggested that this impaired
response, evident in patients with disseminated
disease, might be due to the activity of suppressor
T cells in some cases.
With the introduction of monoclonal antibodies
against human T lymphocyte subsets (Kung et al.,
1979) it has become possible to monitor changes in
the cellular immune system more definitively. These
reagents were used to study breast cancer patients
at all stages and for comparison with healthy
females and patients suffering from benign breast
disease.
Twenty-four healthy females age range 19-62
years were used as controls. They were chosen from
laboratory and nursing staff and blood donors at
the local blood transfusion service. Eighteen
patients (age range, 19-54 years) attending the
surgical outpatient clinic and diagnosed as having
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benign breast disease were studied. Apart from the
presence of a lump in the breast they were in good
health and had not received any form of medical or
surgical therapy for more than 3 months prior to
investigation. The malignant breast disease patients
Stages I-III were studied within the first 24h of
admission to hospital for breast biopsy or
mastectomy and investigated before any treatment.
The stage of disease was determined by routine
investigative procedures and operative findings. Six
Stage I, 2 Stage II and 3 Stage III were studied.
The 7 Stage IV breast cancer patients were studied
either at first presentation (5) or at more than 6
months from preceding chemotherapy or
radiotherapy (2).
Venous blood (20ml) was aspirated from all
subjects and a full blood count and differential
white cell count (DWCC) performed.
Mononuclear cells were isolated from 15ml of
the peripheral venous blood by density gradient
centrifugation on Ficoll Hypaque, (Boyum, 1968)
washed x 2 in Eagles medium and resuspended in
0.01 M sodium phosphate buffered saline +0.1%
azide (PBS) at a concentration of 5 x 106 cellsml-1.
Total peripheral T cell, helper T cell (TH) and
suppressor T cell (T5) subsets were estimated by
indirect immunofluorescence using the OKT series
of monoclonal antibodies (Orthodiagnostics, High
Wycombe, U.K.) OKT3 Pan T cell, OKT4 TH cell
and OKT8 for Ts cell subsets respectively, as
described by Kung et al. (1979).
Aliquots (2001u) of the mononuclear cell
suspension were incubated in solutions (5p1) of
monoclonal antibody at 0°C for 30 min. The cells
were then washed twice with PBS + azide and
resuspended in 100I4 PBS. After a further 30 min
incubation at 0°C in 100pl of a 1:40 dilution of
fluoresceinated goat anti-mouse Ig
(Orthodiagnostics) the percentage of fluorescent
cells was estimated on a Leitz Ortholux II
fluorescent microscope (Leitz, Wetzlar, W.
Germany). The absolute number of each T
lymphocyte subset was calculated from the
differential white cell count (DWCC) and the
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percentage staining with the specific OKT antibody
preparation.
The results for T lymphocyte counts and
nimbers of TH (OKT4+) and TS (OKT8+) cells
were compared for the control, benign and
malignant breast disease groups using the Kruskal-
Wallis one-way' analysis of variance. This test was
also used for the analysis of TH:TS cell ratios.
Comparison of data on patients with malignant
tumours Stage I-III to Stage IV was made by the
Mann-Whitney U-Test.
All subjects studied had a normal white cell
count and DWCC. The T lymphocyte subset results
for the normal populations (Table 1) showed
similar results to those obtained by other
investigators (Kung, 1979; Van Wauwe &
Goossens, 1981). The values for the OKT3, OKT4
and OKT8 populations of the benign breast disease
patients showed no significant difference from those
of the age-matched normal population. The
patients with malignant breast disease had no
signif'icant abnormality in the number of T
lymphocytes (OKT3+) but showed a significantly
reduced number of TH cells (P<0.003) and an
increased number of Ts cells (P<0.001). This,
however, was due to the abnormalities in the
numbers of OKT4+ and OKT8+ cells in patients
with Stage IV disease. The malignant breast cancer
patients had a higher age range, a finding which
was not unexpected. However, within this
population there was no difference in age between
patients with Stages I-III disease (age range 45-71
years) and Stage IV disease (age range 48-75 years).
(Table II).
The ratio TH:TS cells is normally in the range
1:1-2:1 and this result was found in all subjects
studied except for Stage IV breast cancer patients,
all of whom had a TH:TS ratio of <1:1
(P<0.001).
Our findings indicate that patients with breast
cancer have no reduction in the proportion or
Table I Mean values for age, total T cells and T
lymphocyte subsets of control subjects, and patients with
benign and malignant breast disease
Control Benign Malignant
Age(yrs)* 34+ 2.7 38 + 2.7 61 + 2.4
OKT3+(%) 55 + 1.8 58+ 1.6 58 + 1.0
Total T Cells* 1135+82 1181+106 1105+87
OKT4+(%) 37+ 1.7 36+ 1.7 31 + 1.7
TH Cells* 681 +50 725+ 66 587+52
OKT8+(%) 23+ 1.3 23+ 0.9 33 + 2.8
Ts Cells* 414+33 486+ 56 616+54
TH:TS ratio 1.7+ 0.1 1.6+ 0.1 1.1+ 0.1
* ± 1 s.e.
Table II Mean values for age, total T cells and T
lymphocyte subsets. Comparison of breast cancer patients,
Stages I-III to Stage IV
Stage I-III Stage IV
Age (yrs)* 60+ 3.0 64+ 4.3
OKT3+(%) 59+ 2.0 58+ 4.0
Total T Cells* 1224+114.0 919+106.0
OKT4+(%) 35+ 2.0 26+ 2.0
THCells* 703+ 59.0 404+ 34.0
OKT8+(%) 26+ 1.4 45+ 3.5
Ts Cells* 548+ 64.0 723+ 85.0
TH:TS ratio 1.4+ 0.1 0.6+ 0.06
*+1 s.e.
absolute number of T lymphocytes in their
peripheral blood at any stage of disease. Patients
with benign and malignant breast disease Stages I-
III inclusive have normal numbers of T lymphocyte
subsets compared with normal healthy females.
Thus there appears to be no significant numerical
difference in the cellular immune system, as
reflected by the phenotypes of circulating T
lymphocytes of patients with benign and early
malignant breast disease. Patients with Stage IV
breast cancer have normal numbers ofT lymphocytes
but show a markedly reduced number of TH
lymphocytes and an increased number of Ts cells
compared with normal subjects, or patients with
benign or Stage I-III breast cancer. This numerical
alteration in the cellular immune system may
account for the immunosuppresion seen in
advanced stages of the disease and it would be of
interest to ascertain if this finding is associated with
other forms ofadvanced malignancy. It remains an
open question whether this alteration is a causative
factor or a consequence of the disease and what
underlying mechanism results in such a profound
alteration. The 2 patients with Stage IV breast
cancer who had received radiotherapy showed no
sign'ificant difference in the proportions or absolute
number of lymphocyte 'subsets compared to the
other Stage IV patients.
Our findings support the results obtained in
functional assays of cell-mediated immunity in
breast cancer, viz. that patients with advanced
disease have impaired cell-mediated immunity and
that this appears to be due to imbalance of T
lymphocyte subsets with inversion of the normal
TH:TS cell ratio.
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assistance in preparation of the manuscript.PERIPHERAL BLOOD T CELL SUBSETS IN BREAST DISEASE 309
References
BOYUM, A. (1968). Separation of leukocytes from blood
and bone marrow. Scand. J. Clin. Lab. Invest., 21,
(Suppl. 97) 77.
CERVANTES, C., EXPOSITO, G., MORENO, L. & CARCIA,
M.E. (1979). Immunological studies in breast cancer
lymphoid populations. Neoplasma, 26, 711.
CONESA, L.C.G., PASQUALINI, R.S., PUJATO, D. &
LYNCH, M. (1979). Cellular immunity in early human
breast carcinoma. Cell. Mol. Biol., 24, 355.
JERRELLS, T.R., DEAN, J.H. & HERBERMAN, R.B. (1978).
Relationship between T lymphocyte levels and
lymphoproliferative responses to mitogens and
alloantigens in lung and breast cancer patients. Int. J.
Cancer, 21, 282.
KELLER, S.E., IOACHIM, H.L., PEARSE, R. & SILETTI,
D.M. (1976). Decreased T lymphocytes in Patients with
Mammary Cancer. Am. J. Clin. Pathol., 65, 445.
KUNG, P.C., GOLDSTEIN, G., REINHERZ, E.L.
& SCHLOSSMAN, S.F. (1979). Monoclonal antibodies
defining distinctive human T cell surface antigens.
Science, 206, 347.
MENCONI, E., BARZI, A., GRECO, M., CAPRINO, M.C., DE
VECCHIS, L. & MUGGIA, G. (1979). Immunological
profile of breast cancer patients in early or advanced
disease. Experientia, 35, 820.
OSBORNE, C.K., KNIGHT, W.A., YOCHMOWITZ, M.G. &
McGUIRE, W.L. (1980). Modem approaches to the
treatment ofbreast cancer. Blood, 56, 745.
VAN WAUWE, J. & GOOSSENS, J. (1981). Monoclonal
anti-human T-lymphocyte antibodies: Enumeration
and characterization of T-cell subsets. Immunology, 42,
157.
WHITTAKER, M.G. & CLARK, C.G. (1971). Depressed
lymphocyte function in carcinoma of the breast. Br. J.
Surg., 58, 717.
ZEMBALA, M., MYTAR, B., POPIELA, T. & ASHERSON,
G.L. (1977). Depressed in vitro peripheral blood
lymphocyte response to mitogens in cancer patients:
The role ofsuppressor cells. Int. J. Cancer, 19, 605.